| Code | CSB-RA011614MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Canakinumab, targeting human interleukin-1 beta (IL1B), a potent pro-inflammatory cytokine central to innate immune responses. IL1B plays a critical role in mediating inflammatory reactions, fever, and acute phase responses by binding to the IL-1 receptor and activating downstream signaling cascades including NF-κB and MAPK pathways. Dysregulated IL1B production is implicated in numerous autoinflammatory conditions, including cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis, adult-onset Still's disease, gout, and atherosclerotic cardiovascular disease. Elevated IL1B levels have also been associated with various inflammatory disorders and contribute to chronic inflammation in metabolic diseases.
Canakinumab is a fully humanizedized IgG1 monoclonal antibody that specifically neutralizes IL1B with high affinity, preventing its interaction with IL-1 receptors. This biosimilar antibody serves as a valuable research tool for investigating IL1B-mediated inflammatory pathways, studying cytokine signaling mechanisms, and exploring therapeutic interventions in autoinflammatory disease models. It enables researchers to examine the role of IL1B in disease pathogenesis and evaluate potential therapeutic strategies.
There are currently no reviews for this product.